A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma

Veterinary Journal

Volumn 194, Issue 1, 2012, Pages 40-47

  Sharif, H ^a   von Euler, H ^a   Westberg, S ^a   He, E ^b   Wang, L ^a   Eriksson, S ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b Sino Swed Molecular Bio Medicine Research Institute   (China)

Author keywords

Biomarker; Canine; Lymphoma; Prognosis; Radioenzymatic method; Thymidine kinase 1

Indexed keywords

DOXORUBICIN; THYMIDINE KINASE 1; THYMIDINE PHOSPHORYLASE;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INTERMETHOD COMPARISON; LEUKEMIA RELAPSE; LYMPHOMA; MALE; MICHAELIS MENTEN KINETICS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; RADIOASSAY; RADIOENZYMATIC ASSAY; REACTION TIME; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOLID TUMOR;

ANIMALS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MALE; RADIOCHEMISTRY; SENSITIVITY AND SPECIFICITY; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

CANIS FAMILIARIS;

EID: 84868213915     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.03.006     Document Type: Article

References (35)

1. Dorn R.C., Taylor D.O., Hibbard H.H. Epizootiologic characteristics of canine and feline leukemia and lymphoma. American Journal of Veterinary Research 1967, 28:933-1001.
2. Ellims P.H., Eng Gan T., Medley G., Van Der Weyden M.B. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood 1981, 58:926-930.
3. Eriksson S., Munch-Petersen B., Johansson K., Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cellular and Molecular Life Science 2002, 59:1327-1346.
4. Gronowitz J.S., Hagberg H., Kallander C.F., Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. British Journal of Cancer 1983, 47:487-495.
5. Gronowitz J.S., Steinholtz L., Kallander C.F., Hagberg H., Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer 1986, 58:111-118.
6. Hallek M., Wanders L., Strohmeyer S., Emmerich B. Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Annals of Hematology 1992, 65:1-5.
7. Hallek M., Wanders L., Ostwald M., Busch R., Senekowitsch R., Stern S., Schick H.D., Kuhn-Hallek I., Emmerich B. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leukemia and Lymphoma 1996, 22:439-447.
8. Hallek M., Touitou Y., Levi F., Mechkouri M., Bogdan A., Bailleul F., Senekowitsch R., Emmerich B. Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. Clinica Chimica Acta 1997, 267:155-166.
9. Hallek M., Langenmayer I., Nerl C., Knauf W., Dietzfelbinger H., Adorf D., Ostwald M., Busch R., Kuhn-Hallek I., Thiel E., Emmerich B. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999, 93:1732-1737.
10. Hassig M., Casal M., Von Beust B., Nussbaumer M., Rusch P. CEA test in domestic animals. Schweizer Archiv fur Tierheilkunde 1991, 133:311-313.
11. He Q., Skog S., Tribukait B. Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumours. Cell Proliferation 1991, 24:3-14.
12. Huang S., Lin J., Guo N., Zhang M., Yun X., Liu S., Zhou J., He E., Skog S. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression. Asian Pacific Journal of Cancer Prevention 2011, 12:497-505.
13. Ke P.Y., Chang Z.F. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Molecular and Cellular Biology 2004, 24:514-526.
14. Ke P.Y., Yang C.C., Tsai I.C., Chang Z.F. Degradation of human thymidine kinase is dependent on serine-13 phosphorylation: Involvement of the SCF-mediated pathway. Biochemical Journal 2003, 370:265-273.
15. Konoplev S.N., Fritsche H.A., O'Brien S., Wierda W.G., Keating M.J., Gornet T.G., St Romain S., Wang X., Inamdar K., Johnson M.R., Medeiros L.J., Bueso-Ramos C.E. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. American Journal of Clinical Pathology 2010, 134:472-477.
16. Lechowski R., Jagielski D., Hoffmann-Jagielska M., Zmudzka M., Winnicka A. Alpha-fetoprotein in canine multicentric lymphoma. Veterinary Research Communication 2002, 26:285-296.
17. Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
18. Munch-Petersen B. Differences in the kinetic properties of thymidine kinase isoenzymes in unstimulated and phytohemagglutinin-stimulated human lymphocytes. Molecular and Cellular Biology 1984, 64:173-185.
19. Musto P., Bodenizza C., Falcone A., D'Arena G., Scalzulli P., Perla G., Modoni S., Parlatore L., Valvano M.R., Carotenuto M. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: Relationship to development of acute myeloid leukaemia. British Journal of Haematology 1995, 90:125-130.
20. Nakamura N., Momoi Y., Watari T., Yoshino T., Tsujimoto H., Hasegawa A. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. Journal of Veterinary Medical Sciences 1997, 59:957-960.
21. Owen, L.N., 1980. Lymphoid and haematopoietic tissues (including lymphosarcoma of skin). In: TNM Classification of Tumours in Domestic Animals. World Health Organization, Geneva, Switzerland, pp. 46-47 (Chapter 9).
22. Pan, Z.L., Ji, X.Y., Shi, Y.M., Zhou, J., He, E., Skog, S., 2010. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. Journal of Cancer Research and Clinical Oncology, February 7. [Epub ahead of print].
23. Piek C.J., Rutteman G.R., Teske E. Evaluation of the results of a l-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Veterinary Quarterly 1999, 21:44-49.
24. Roels S., Tilmant K., Ducatelle R. PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs. Journal of Comparative Pathology 1999, 121:13-24.
25. Svobodova S., Topolcan O., Holubec L., Treska V., Sutnar A., Rupert K., Kormunda S., Rousarova M., Finek J. Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Research 2007, 27:1907-1909.
26. Teske E. Canine malignant lymphoma: A review and comparison with human non-Hodgkin's lymphoma. Veterinary Quarterly 1994, 16:209-219.
27. Topolcan O., Holubec L. The role of thymidine kinase in cancer disease. Expert Opinion on Medical Diagnostics 2008, 2:129-141.
28. Topolcan O., Holubec L., Finek J., Stieber P., Holdenrieder S., Lamerz R., Holubec Sen L., Svobodova S., Visokai V., Lipska L. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Research 2005, 25:1831-1833.
29. Wang L., Eriksson S. 5-Bromovinyl 2'-deoxyuridine phosphorylation by mitochondrial and cytosolic thymidine kinase (TK2 and TK1) and its use in selective measurement of TK2 activity in crude extracts. Nucleosides, Nucleotides & Nucleic Acids 2008, 27:858-862.
30. von Euler H., Eriksson S. Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases. Veterinary and Comparative Oncology 2011, 9:1-15.
31. von Euler H., Einarsson R., Olsson U., Lagerstedt A.S., Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: A potent marker for prognosis and monitoring the disease. Journal of Veterinary Internal Medicine 2004, 18:696-702.
32. von Euler H.P., Rivera P., Aronsson A.C., Bengtsson C., Hansson L.O., Eriksson S.K. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity - Evaluation of a new, fully automated non-radiometric assay. International Journal Oncology 2008, 34:505-510.
33. Zanatta R., Abate O., D'Angelo A., Miniscalco B., Mannelli A. Diagnostic and prognostic value of serum lactate dehydrogenase (LDH) and LDH isoenzymes in canine lymphoma. Veterinary Research Communication 2003, 27:449-452.
34. Zhang J., Jia Q., Zou S., Zhang P., Zhang X., Skog S., Luo P., Zhang W., He Q. Thymidine kinase 1: A proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncology Reports 2006, 15:455-461.
35. öhrvik A., Lindh M., Einarsson R., Grassi J., Eriksson S. Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clinical Chemistry 2004, 50:1597-1606.